RN7SL322P

Across TCGA pan-cancer cohorts, RN7SL322P RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RN7SL322P’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RN7SL322P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL322P is over-expressed in tumor, although a few such as KIRP and COAD show the opposite, repressed pattern.

LIHC, PRAD, and LUAD are the cancer types where RN7SL322P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RN7SL322P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.069	.010	4	view →
PRAD	All	All	+0.082	.007	2	view →
LUAD	Female	All	+0.061	.015	2	view →
KIRP	All	II,III,IV	−0.083	.030	1	view →
COAD	All	II,III,IV	−0.048	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RN7SL322P–LIHC

Open the LIHC breakdown →